XML 67 R31.htm IDEA: XBRL DOCUMENT v3.20.4
Segment Information and Concentration of Business Risk (Tables)
 12 Months Ended
Dec. 31, 2020
Segment Information and Concentration of Business Risk [Abstract]  
Segment Information

The following tables show our segment revenue and income (loss) from operations for 2020, 2019 and 2018 (in thousands), respectively.

2020
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
286,583
    
$
—
    
$
—
    
$
286,583
  
Product sales, net
    
—
      
69,999
      
—
      
69,999
  
Licensing and other royalty revenue
    
11,334
      
—
      
(3,217
)
    
8,117
  
Total commercial revenue
    
297,917
      
69,999
      
(3,217
)
    
364,699
  
R&D revenue under collaborative agreements
    
325,024
      
82,321
      
(42,780
)
    
364,565
  
Total segment revenue
  
$
622,941
    
$
152,320
    
$
(45,997
)
  
$
729,264
  
Total operating expenses
  
$
563,647
    
$
389,575
    
$
(51,876
)
  
$
901,346
  
Income (loss) from operations
  
$
59,294
    
$
(237,255
)
  
$
5,879
    
$
(172,082
)

2019
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
292,992
    
$
—
    
$
—
    
$
292,992
  
Product sales, net
    
—
      
42,253
      
—
      
42,253
  
Licensing and other royalty revenue
    
12,616
      
10,172
      
(5,583
)
    
17,205
  
Total commercial revenue
    
305,608
      
52,425
      
(5,583
)
    
352,450
  
R&D revenue under collaborative agreements
    
553,038
      
436,118
      
(219,007
)
    
770,149
  
Total segment revenue
  
$
858,646
    
$
488,543
    
$
(224,590
)
  
$
1,122,599
  
Total operating expenses
  
$
523,207
    
$
450,469
    
$
(216,960
)
  
$
756,716
  
Income (loss) from operations
  
$
335,439
    
$
38,074
    
$
(7,630
)
  
$
365,883
  

2018
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
237,930
    
$
—
    
$
—
    
$
237,930
  
Product sales, net
    
—
      
2,237
      
—
      
2,237
  
Licensing and other royalty revenue
    
2,755
      
12,000
      
—
      
14,755
  
Total commercial revenue
    
240,685
      
14,237
      
—
      
254,922
  
R&D revenue under collaborative agreements
    
401,259
      
50,630
      
(107,137
)
    
344,752
  
Total segment revenue
  
$
641,944
    
$
64,867
    
$
(107,137
)
  
$
599,674
  
Total operating expenses
  
$
380,212
    
$
295,683
    
$
(14,849
)
  
$
661,046
  
Income (loss) from operations
  
$
261,732
    
$
(230,816
)
  
$
(92,288
)
  
$
(61,372
)


The following table shows our total assets by segment at December 31, 2020 and 2019 (in thousands), respectively.

Total Assets
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
December 31, 2020
  
$
2,792,222
    
$
435,824
    
$
(838,291
)
  
$
2,389,755
  
December 31, 2019
  
$
3,478,081
    
$
599,250
    
$
(844,219
)
  
$
3,233,112